SC
VRTX icon

Schubert & Co’s Vertex Pharmaceuticals VRTX Stock Holding History

Schubert & Co’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-33
Closed -$10.4K – 1479
2023
Q1 		$10.4K Sell
33
-8
-20% -$2.4K 0.01% 214
2022
Q4 		$11.8K Sell
41
-2
-5% -$610 0.01% 195
2022
Q3 		$12K Buy
43
+11
+34% +$3.17K 0.01% 171
2022
Q2 		$9K Buy
32
+19
+146% +$5.08K 0.01% 200
2022
Q1 		$3K Buy
13
+4
+44% +$949 ﹤0.01% 317
2021
Q4 		$2K Buy
+9
New +$1.75K ﹤0.01% 465

Other funds holding VRTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Schubert & Co's VRTX Position: Q2 2023 in Review

Schubert & Co sold out of Vertex Pharmaceuticals (VRTX) in Q2 2023, closing a stake of 33 shares — an estimated $10.4K sold.

Schubert & Co first reported a position in VRTX in Q4 2021 and held it in 6 quarters. The position peaked at $12K in Q3 2022. 1,285 funds tracked by Wall St. Rank hold VRTX as of Q2 2023.

  • Schubert & Co reported no remaining Vertex Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
  • Schubert & Co sold 33 Vertex Pharmaceuticals shares in Q2 2023, an estimated $10.4K.
  • Schubert & Co first reported a position in Vertex Pharmaceuticals in Q4 2021 and held it in 6 quarters.
  • Schubert & Co's Vertex Pharmaceuticals position peaked at $12K in Q3 2022.
  • 1,285 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2023.

Based on Schubert & Co's 13F filing for Q2 2023, filed 4 Aug 2023.